Health and Healthcare

Gilead Sciences : GILD

All Gilead Sciences Articles

736 Articles

Chris Lange | Jul 27, 2016 at 7:50 AM EDT

Major Biotechs See Increased Short Interest Bets

The short interest data are out for the July 15 settlement date. Short interest increased across many of these selected…

Chris Lange | Jul 26, 2016 at 11:50 AM EDT

Why Analysts Are Thinking M&A Is Back on the Table for Gilead

Overall, the Gilead Sciences report was not good and investors took to dumping the stock. On the other hand, this…

Jon C. Ogg | Jul 26, 2016 at 8:50 AM EDT

Top Analyst Upgrades and Downgrades: Gilead, Sprint, Starbucks, Southwest Air, Texas Instruments, Disney, Nordstrom and More

The top analyst upgrades, downgrades and initiations seen on Tuesday morning include Gilead Sciences, Sprint, Starbucks, Southwest Airlines, Texas Instruments,…

Chris Lange | Jul 25, 2016 at 4:37 PM EDT

Why Analysts Were Not Satisfied With Gilead Earnings

Although Gilead Sciences is one of the world’s leading biotech companies, an earnings beat in its latest report was not…

Chris Lange | Jul 25, 2016 at 9:05 AM EDT

What to Expect From Gilead Sciences Earnings

Gilead Sciences is scheduled to release its second-quarter financial results after the markets close on Monday.

Chris Lange | Jul 24, 2016 at 10:12 AM EDT

10 Must-See Earnings for the Coming Week

24/7 Wall St. has put together a preview of Alphabet, Amazon.com, Facebook and some of the other major companies reporting…

Jon C. Ogg | Jul 14, 2016 at 8:40 AM EDT

5 Companies Likely Buying Back the Most Stock in June and July

With many stocks having just hit record highs, investors need at least a bit of an explanation here. One thing…

Chris Lange | Jul 13, 2016 at 8:10 AM EDT

Short Sellers Become More Selective on Major Biotechs

The June 30 short interest data have been compared with the previous report, and short interest moves were mixed in…

Chris Lange | Jul 12, 2016 at 10:10 AM EDT

Biotechs With Drug Pipelines Closest to Zero Valuation

Credit Suisse has taken a look at which biotech companies in its coverage have the least credit given to pipeline…

Jon C. Ogg | Jun 28, 2016 at 12:01 PM EDT

5 Top Biotechs Where Future Multi-Billion Dollar Drug Pipelines are Valued Almost at Zero

[cnxvideo id=”655353″ placement=”ros”]Sometimes market volatility and outside shocks create a rift between market prices and real value. That may currently…

Chris Lange | Jun 27, 2016 at 7:55 AM EDT

Short Sellers Run for Cover From Major Biotechs

The short interest data are out for the June 15 settlement date. Biotech companies are considered a riskier group of…

Jon C. Ogg | Jun 23, 2016 at 8:05 AM EDT

20 Companies Buying Back the Most Stock in 2016

Standard & Poor's has now shown that the first quarter of 2016 saw a 12% rise in buyback spending to…

Chris Lange | Jun 20, 2016 at 12:25 PM EDT

Gilead Sciences Bounces on Preliminary Results

Shares of Gilead Sciences Inc. (NASDAQ: GILD) saw make a handy gain just off of their 52-week low following the release of…

Chris Lange | Jun 10, 2016 at 8:10 AM EDT

Short Sellers Become More Selective on Major Biotechs

The May 31 short interest data have been compared with the previous report, and short interest moves were mixed in…

Jon C. Ogg | May 26, 2016 at 8:10 AM EDT

7 Companies in the Fight to Defeat the Zika Virus

Many companies are being discussed as Zika virus winners, but the reality is that many of them are so small…

1 … 25 26 27 28 29 … 50

Gilead Sciences : GILD

All Gilead Sciences Articles

Major Biotechs See Increased Short Interest Bets

Why Analysts Are Thinking M&A Is Back on the Table for Gilead

Top Analyst Upgrades and Downgrades: Gilead, Sprint, Starbucks, Southwest Air, Texas Instruments, Disney, Nordstrom and More

Why Analysts Were Not Satisfied With Gilead Earnings

What to Expect From Gilead Sciences Earnings

10 Must-See Earnings for the Coming Week

5 Companies Likely Buying Back the Most Stock in June and July

Short Sellers Become More Selective on Major Biotechs

Biotechs With Drug Pipelines Closest to Zero Valuation

5 Top Biotechs Where Future Multi-Billion Dollar Drug Pipelines are Valued Almost at Zero

Short Sellers Run for Cover From Major Biotechs

20 Companies Buying Back the Most Stock in 2016

Gilead Sciences Bounces on Preliminary Results

Short Sellers Become More Selective on Major Biotechs

7 Companies in the Fight to Defeat the Zika Virus

Tilray Jumps 6%, Canopy Growth Climbs 3%, Aurora Cannabis Gains 4%: Here’s Why TLRY Is Still Down 47% YTD

A Top Strategist Says Buy “Anything but the S&P 500” as Small Caps Quietly Steal the Lead

He Retired From Lobstering, Bought a Deli, and Left the Profit in the Business. Social Security Counted It Anyway.

He Retired From Lobstering, Bought a Deli, and Left the Profit in the Business. Social Security Counted It Anyway.

Company Stock in a 401(k) Gets a Special Tax Break. One Standard Rollover Erases It Forever.

Tilray Jumps 6%, Canopy Growth Climbs 3%, Aurora Cannabis Gains 4%: Here’s Why TLRY Is Still Down 47% YTD

A Top Strategist Says Buy “Anything but the S&P 500” as Small Caps Quietly Steal the Lead

Gilead Sciences : GILD

All Gilead Sciences Articles

Major Biotechs See Increased Short Interest Bets

Why Analysts Are Thinking M&A Is Back on the Table for Gilead

Top Analyst Upgrades and Downgrades: Gilead, Sprint, Starbucks, Southwest Air, Texas Instruments, Disney, Nordstrom and More

Why Analysts Were Not Satisfied With Gilead Earnings

What to Expect From Gilead Sciences Earnings

10 Must-See Earnings for the Coming Week

5 Companies Likely Buying Back the Most Stock in June and July

Short Sellers Become More Selective on Major Biotechs

Biotechs With Drug Pipelines Closest to Zero Valuation

5 Top Biotechs Where Future Multi-Billion Dollar Drug Pipelines are Valued Almost at Zero

Short Sellers Run for Cover From Major Biotechs

20 Companies Buying Back the Most Stock in 2016

Gilead Sciences Bounces on Preliminary Results

Short Sellers Become More Selective on Major Biotechs

7 Companies in the Fight to Defeat the Zika Virus

Tilray Jumps 6%, Canopy Growth Climbs 3%, Aurora Cannabis Gains 4%: Here’s Why TLRY Is Still Down 47% YTD

A Top Strategist Says Buy “Anything but the S&P 500” as Small Caps Quietly Steal the Lead

He Retired From Lobstering, Bought a Deli, and Left the Profit in the Business. Social Security Counted It Anyway.

Featured Reads

He Retired From Lobstering, Bought a Deli, and Left the Profit in the Business. Social Security Counted It Anyway.

Company Stock in a 401(k) Gets a Special Tax Break. One Standard Rollover Erases It Forever.